130 related articles for article (PubMed ID: 3152957)
41. The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia.
Wilson R; Osborne C; Halsey C
Paediatr Drugs; 2018 Aug; 20(4):293-301. PubMed ID: 29850985
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
43. Aminoterminal propeptide of type III procollagen in cerebrospinal fluid. Variation with age and in childhood leukemia.
Vainionpää L; Risteli L; Lanning M; Myllylä V; Risteli J
Clin Chim Acta; 1991 Nov; 203(1):47-56. PubMed ID: 1769120
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
45. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
46. Carboxyterminal propeptide of type I procollagen in cerebrospinal fluid in childhood and in children with leukemia undergoing intrathecal treatment.
Vainionpää L; Risteli L; Lanning M; Risteli J
Clin Chem; 1991 Aug; 37(8):1365-9. PubMed ID: 1868595
[TBL] [Abstract][Full Text] [Related]
47. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
48. [Pharmacokinetics of methotrexate in children with acute lymphoblastic leukemia].
Lares-Asseff I; Paredes R; Taboada C; Cravioto J; Velázquez M; Roldán RM; Faisal AG
Bol Med Hosp Infant Mex; 1988 Oct; 45(10):671-80. PubMed ID: 3264171
[No Abstract] [Full Text] [Related]
49. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
[TBL] [Abstract][Full Text] [Related]
50. Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.
Wang Y; Lantin E; Sutow WW
Clin Chem; 1976 Jul; 22(7):1053-6. PubMed ID: 1277503
[TBL] [Abstract][Full Text] [Related]
51. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Ochs J; Rodman J; Abromowitch M; Kavanagh R; Harris M; Yalowich J; Rivera GK
J Clin Oncol; 1991 Jan; 9(1):139-44. PubMed ID: 1985163
[TBL] [Abstract][Full Text] [Related]
52. 2,4-diamino-7-hydroxy-pteridines in biological fluids of patients on high-dose methotrexate.
Dhondt JL; Millot F; Hayte JM; Mazingue F; Farriaux JP
Clin Chim Acta; 1993 Nov; 220(2):189-200. PubMed ID: 8111963
[TBL] [Abstract][Full Text] [Related]
53. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
Borsi JD; Schuler D; Moe PJ
Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
[TBL] [Abstract][Full Text] [Related]
54. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
55. Regional cerebral blood flow and neuron-specific enolase in cerebrospinal fluid in children with acute lymphoblastic leukemia during induction treatment.
Osterlundh G; Bjure J; Lannering B; Kjellmer I; Uvebrant P; Márky I
J Pediatr Hematol Oncol; 1999; 21(5):378-83. PubMed ID: 10524450
[TBL] [Abstract][Full Text] [Related]
56. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
57. Rational use of methotrexate in maintenance therapy of childhood acute lymphoblastic leukemia.
Wang ZH; Yu ZL
Chin Med J (Engl); 1992 Feb; 105(2):147-52. PubMed ID: 1597076
[TBL] [Abstract][Full Text] [Related]
58. Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2.
Wormdal OM; Flægstad T; Stokland T
Pediatr Hematol Oncol; 2018; 35(5-6):350-354. PubMed ID: 30672361
[TBL] [Abstract][Full Text] [Related]
59. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.
Kellie SJ; Barbaric D; Koopmans P; Earl J; Carr DJ; de Graaf SS
Cancer; 2002 Mar; 94(6):1815-20. PubMed ID: 11920545
[TBL] [Abstract][Full Text] [Related]
60. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
